[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Minicircle\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100609607","phase-1-safety-and-efficacy-of-injectable-klotho-plasmid-gene-therapy-in-humans-100609607",false,"NCT07216781","Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans","Evaluating the Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans: An Interventional, Non-Placebo-Controlled Pilot Phase Study","Inclusion Criteria:\n\n* Participant is open to morphological change\n* If female, participant agrees to maintain contraception\n* If female, participant agrees to take a pregnancy test\n* If female, participant agrees to a pregnancy waiver\n\nExclusion Criteria:\n\n* Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study\n* History of cancer diagnosis\n* Preexisting medical issues that may be exacerbated by the treatment\n* Has received any gene therapy within the past 12 months\n* Unwilling or unable to provide written informed consent",true,"ALL","23 Years","90 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to investigate the safety and efficacy of a gene therapy for Klotho, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of the Klotho gene therapy.",[28],"Healthy Adults",[30,31,32],"Klotho","plasmid","gene therapy","RECRUITING","2026-02-15",{"date":36,"type":37},"2026-02-17","ACTUAL",{"date":39,"type":37},"2025-10-06",{"date":41,"type":22},"2026-08",{"name":43,"class":44},"Minicircle","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100614902","early-phase-1-safety-and-efficacy-of-klotho-and-follistatin-gene-therapy-100614902","NCT07285629","Safety and Efficacy of Klotho and Follistatin Gene Therapy","Evaluating the Safety and Efficacy of Injectable Combination Klotho and Follistatin Plasmid Gene Therapy in Humans -- An Interventional, Non-Placebo Controlled Pilot Phase Study","Inclusion Criteria:\n\n* Adults aged 50 to 80 years\n* General good health\n* Willing to comply with all study-related procedures and visits\n* Participant is open to morphological change\n* If female, participant agrees to maintain contraception\n* If female, participant agrees to take a pregnancy test\n* If female, participant agrees to a pregnancy waiver\n\nExclusion Criteria:\n\n* Currently enrolled in another clinical trial\n* History of cancer, autoimmune disease, or chronic kidney\u002Fliver disease\n* Use of immunosuppressive therapy\n* Pregnant or breastfeeding\n* Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study.\n* Regular use of NMDA (N-methyl-D-aspartate) antagonists (i.e., memantine, ketamine, etc.)\n* Regular use of antiplatelet medications (i.e., aspirin)\n* Any medical or psychiatric condition that could interfere with participation or pose safety concerns\n* Unwilling or unable to provide informed consent","50 Years","80 Years",{"count":55,"type":22},30,[57],"EARLY_PHASE1","The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.",[28],[61,62,63,32,31],"klotho","follistatin","nonviral","2026-01-06",{"date":66,"type":37},"2026-01-08",{"date":68,"type":37},"2025-12-16",{"date":70,"type":22},"2026-06",{"name":43,"class":44},""]